Defining radiation target volumes for glioblastoma from predictions of tumor recurrence with AI and diffusion & metabolic MRI
Nate Tran(University of California, San Francisco), Janine Lupo, Tracy Luks(University of California, San Francisco), Javier Villanueva‐Meyer(Baylor College of Medicine), Jennifer Clarke(Cornell University), Yan Li(Hebei Medical University), Ozan Genc, Susan Chang(University of San Francisco), Steve Braunstein(University of California, San Francisco), Oluwaseun Adegbite(University of California, San Francisco), Jacob Ellison(University of California, San Francisco), Nicholas Butowski(University of California, San Francisco), Bo Liu(Central Hospital of Wuhan), Hui Lin, Olivier Morin(University of California, San Francisco), Angela Jakary(University of California, San Francisco)
Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition
August 14, 2024
Cited by 0
Related Papers
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Estimating Survival in Patients With Lung Cancer and Brain Metastases
|JAMA Oncology|2016|655
Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer’s Disease using structural MR and FDG-PET images
|Scientific Reports|2018|380
Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
|Journal of Clinical Oncology|2008|377